// App-Quantinova.ai

13 : PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Johann S. De Bono

Principal Investigators

  • Christopher Sweeney

  • Sergio Bracarda

  • Cora N. Sternberg

  • Kim N. Chi

  • David Olmos

  • Shahneen Kaur Sandhu

  • Christophe Massard

  • Nobuaki Matsubara

  • Josep Garcia

  • Malgorzata Nowicka

  • Matthew Wongchenko

  • Zhen Shi

Medical Centers

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

  • Dana-Farber Cancer Institute, Boston, MA

  • Azienda Ospedaliera S.Maria, Terni, Italy

  • Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY.

  • BC Cancer Agency, Vancouver, BC, Canada

  • CNIO - Spanish National Cancer Research Center, Madrid, Spain

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Institut Gustave-Roussy, Villejuif, France

  • National Cancer Center Hospital, Tokyo, Japan

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech, Inc., South San Francisico, CA

Locations

  • United Kingdom

  • United States

  • Italy

  • Canada

  • Spain

  • Australia

  • France

  • Japan

  • Switzerland

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Phosphatase and tensin homolog

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • PI3K/AKT

Drug/Treatment

  • CB-7598

  • Ipatasertib

  • Methadone hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT03072238

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved